Testimonials

Since Tri-Solfen^® was commercially launched, over 150 million lambs have been treated and over 80% of Australian wool growers are now using Tri-Solfen for their sheep. Here’s what some of them have to say…

‘We have used pain relief for two years now and seen real production gains. We are concerned for the welfare of our animals and will continue to use pain relief to ensure they get the best care.’

Clinton Wise– Wililoo Merino Stud, Woodanilling, W.A.

'It easy to see the difference pain relief makes. Before, lambs would walk away hunched up, even taking a couple of hours to walk back to the paddock. Now they run straight back to Mum and start suckling,” says Rod. “My wool is now sold under the Better Choices brand. I see this as a definite advantage. I think it will be an advantage in the long run, to both me and the industry as a whole.'

Rod Miller– Glenpaen Merino Stud, Horsham, Vic

'After being treated with pain relief my lambs were more content and less stressed. As farmers we are sincere in looking after the welfare of our animals and using pain relief demonstrates this.'

Richard Coole– Frankland, W.A.

'We have been using pain relief for the past three years. We’re impressed by reduced bleeding in the mulesing wound immediately after application. Lambs run straight back to find the ewe, which has dramatically reduced our mortality rates. Flock management, post lamb marking is easier due to the effect of pain relief and the scab healing faster.'

Ryan & Malcom O’Dea– Peepingee Merino Stud, Narrogin, W.A.

'Using pain relief eases the stress and allows lambs to mother up and move back to the paddock easier with faster weight gains.'

Kent Lummis– Waverley Downs, Gilgandra, NSW

Country	Species	Patent
Australia	Sheep	Granted
Australia	Horses, Dogs, Lab animals	Granted
Australia	Cattle	Granted
Australia	Humans	Granted
New Zealand	Sheep, Cattle	Granted
New Zealand	Horses, Dogs, Lab animals	Granted
EU	Humans	Granted
EU	Pig, Sheep, Cattle	Granted
USA	Dogs, Horses, Lab animals	Granted
USA	Humans	Granted
USA	Pig, Sheep, Cattle	Granted
Canada	Horses, Dogs, Lab animals	Granted
Canada	Cattle, Pig	Granted
Canada	Humans	Granted

Advisory Board

Ian Page

Non-Executive Director

Ian is Chief Executive Officer of Dechra Pharmaceuticals, which has a 33% shareholder in Medical Ethics. He joined National Veterinary Services, Dechra’s former services business in 1989 and joined the Board of Dechra in 1997. In October 2010, Ian was appointed as Non-Executive Chairman of Sanford DeLand Asset Management.

Dr Chris Roberts

Human Wound and Regulatory Advisor

Chris has over 20 years’ line management experience of heading clinical research teams. He was previously global head of Smith & Nephew clinical support and market development, where he managed global clinical Phase II and III programmes in the management of venous and pressure ulcers.

Lieutenant Colonel Professor Steven Jeffery

Medical Specialist Advisor

Steve has over 15 years’ experience in military plastic surgery. In 2011 he was awarded the Military Civilian Partnership Award for ‘Regular of the Year’, as well as receiving the Wounds UK ‘Key Contribution’ award and the Smith and Nephew ‘Customer Pioneer of the Year’ award. He has also been awarded Fellowship of the Royal College of Surgeons of England ad eundum. He is an expert adviser to NICE Medical Technologies Evaluation Programme. Steve co-founded the Woundcare 4 Heroes charity, which is already making a big difference to the wound care of both serving and veteran personnel.

Dr Matthew Bayfield

Medical Specialist Scientific Director

Dr Matthew Bayfield, Head of Cardiothoracic Surgery, Strathfield Private Hospital and VMO Cardiothoracic Surgeon, Royal Prince Alfred Hospital.

Professor Peter Windsor

Veterinarian Research Advisor

Peter is a registered specialist veterinary surgeon in New South Wales and an emeritus Professor at Sydney University. He holds a BVSc (Hons), PhD, DVSc and diploma from the European College of Small Ruminant Health Management.

Dr Julian Braidwood

Global Regulatory Affairs Advisor

Julian has held leadership roles and managed international clinical projects with Grampian. He was previously Regulatory Affairs Manager at Novartis Animal Health. He is the Founder and Managing Director of Triveritas, where he is responsible for a team of 40 animal health specialists across the EU and the US.

Tri–Solfen^®

Tri-Solfen^® is a local anaesthetic and antiseptic gel spray that adheres well to wounds and acts as a barrier to environmental stimuli, promotes haemostasis and improves wound healing. Tri-Solfen^® contains two proven topical local anaesthetics; fast-acting Lignocaine for immediate pain relief and long-acting bupivacaine for prolonged post-operative pain relief. Adrenaline is included for its ability to reduce the shock and stress of blood loss, whilst prolonging the anaesthetic action. Tri-Solfen^® also contains Cetrimide; an antiseptic widely used to cleanse skin and wounds and provides protection from bacterial contamination.

Allan Giffard

Co-Founder, Managing Director

Allan has a successful track record in the development and commercialisation of market leading products in animal nutrition, health and welfare. He has extensive international experience in successfully negotiating license and distribution agreements with major pharmaceutical companies. He also has vast experience in developing and presenting improved animal welfare programmes and standards, as well as supply chain traceability for incorporation into global retailers CSR policies and their supply chain.

Previously, Allan has been an advisor to the Australian Wool Innovation, Landmark, Bayer Healthcare and Virbac Animal Health.

Dr Meredith Sheil

Co-Founder, Chief Medical Officer

Meredith is a specialist paediatrician with clinical and medical research experience and is the inventor of Medical Ethics’ lead product, Tri-Solfen®. Her 30 years of experience includes paediatric accident and emergency, paediatric post-operative cardiac intensive care, wound management and mitigation of pain and inflammation. She holds a MBBS and PhD from Sydney University Department of Paediatrics and Child Health and is a Fellow of the Royal Australasian College of Physicians.

In addition, Meredith has over 18 years’ experience in primary production, animal husbandry, wool and sheep meat production, land care and management. She has a strong background in corporate and research governance as an Executive Director of the Australian Wool Innovation, Chair Science and Welfare Committee, and The Woolmark Company. She is a past local government councillor, Deputy Mayor and Chair of the Conservation Committee Hunters Hill Council in New South Wales, Australia.

Charles Olsson

Co-Founder, Communication and Business Development Director

Charles has extensive experience in the Australian Agri business, including livestock nutrition and stock medicine manufacturing, sheep and wool production, and salt mining. He has sat on various Agricultural industry boards, including directorships on Australian Wool Innovation, chairing marketing and Intellectual property divisions of Woolmark and AWI.

Bachelor of Economics. Major Accounting. Macquarie University. Member of the Australian Institute of Company Directors

Currently Managing Director of Four Seasons PTY LTD, a national livestock supplement company supplying 400 rural retailers throughout Australia, exporting to NZ and South East Asia.

About Medical Ethics

Medical Ethics is focused on mitigating pain and minimising suffering from wounds

Medical Ethics is a commercial and development stage life science company focused on pain mitigation in wounds for humans and animals.

Through Medical Ethics’ proven, patent protected platform technology, we have identified a transformational way of mitigating pain and minimising suffering associated with wounds.

The first and only topical pain and wound management product for livestock

We are developing our technology to minimise wound pain in humans

Humans and animals

There has to be a better solution for the treatment of chronic wound pain, leg ulcer pain and accidental wounds

In humans, we are investing in the development of our technology for the treatment of chronic wounds such as venous leg ulcers. We have also identified future near-term opportunities for application in the treatment of traumatic wounds caused by surgical procedures and mass trauma situations such as accidents, military conflict and natural disasters.

Animal welfare and helping animals recover quicker from surgical procedures is at the heart of what we do

In animals, our technology supports wound care required for surgical procedures in sheep, pigs, cattle, equine and companion animals. We are the first, and currently the only, company globally to develop, launch and commercialise a topical pain and wound management product for use in livestock undergoing painful surgical procedures, such as dehorning, tail docking, castration and fly-strike prevention.

Our vision and mission

Our vision…

Develop and deliver highly effective, safe, affordable and practical pain mitigation and accelerated wound healing products, to prevent pain and minimise suffering associated with wounds in humans, livestock and companion animals.

Our mission…

End unnecessary suffering from wound pain and accelerate the healing process.

Our strategy

Become a world leader in pain and wound care products

Medical Ethics’ primary objective is to develop world leading products from our patented and commercially proven IP and to seek regulatory approvals for both humans and animals in key global markets.

The license agreements will include upfront payments milestones and royalty payments.

This model has proved successful with Medical Ethics securing two multinational pharmaceutical companies to license their technology in animals globally – Dechra Pharmacuticals and Bayer Animal Health.

Discussions have commenced with several interested parties for the distribution of our human products once market approvals have been achieved.

The executive team